Clinical trials
Phase 1/2 Carcinoma, Transitional Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
77 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 9 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 6 |
| 2021 | 9 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 19 |
| Completed | 18 |
| Recruiting | 15 |
| Active, not recruiting | 15 |
| Unknown status | 6 |
| Withdrawn | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Biosciences International Sàrl | 3 |
| Merck Sharp & Dohme LLC | 3 |
| National Cancer Institute (NCI) | 3 |
| Astellas Pharma Global Development, Inc. | 2 |
| Eli Lilly and Company | 2 |
| ImmunityBio, Inc. | 2 |
| Rainier Therapeutics | 2 |
| AEterna Zentaris | 1 |
| Abbisko Therapeutics Co, Ltd | 1 |
| Alentis Therapeutics AG | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 77 |
| Carcinoma, Non-Small-Cell Lung | 32 |
| Urinary Bladder Neoplasms | 22 |
| Carcinoma, Renal Cell | 21 |
| Squamous Cell Carcinoma of Head and Neck | 20 |
| Melanoma | 19 |
| Triple Negative Breast Neoplasms | 17 |
| Stomach Neoplasms | 16 |
| Uterine Cervical Neoplasms | 16 |
| Colorectal Neoplasms | 15 |
Trials
Showing 76 to 77 of 77. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.